Literature DB >> 19318454

Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists.

Mabrouka Doghman1, Julie Cazareth, Dominique Douguet, Franck Madoux, Peter Hodder, Enzo Lalli.   

Abstract

CONTEXT: Transcription factor steroidogenic factor-1 (SF-1) plays a pivotal role in the control of adrenocortical cell steroidogenesis and proliferation. SF-1 amplification and overexpression are found in most cases of childhood adrenocortical tumors (ACTs).
OBJECTIVE: Our objective was to investigate the effect of SF-1 inverse agonists of the alkyloxyphenol and isoquinolinone classes on the proliferation of human adrenocortical cell lines expressing SF-1 (H295R), in conditions of basal and increased SF-1 expression, or negative for SF-1 expression (SW-13). MAIN OUTCOME MEASURES: Proliferation assays, immunoblots, flow cytometric analyses, steroid hormone assays, and reverse transcription quantitative PCR were used.
RESULTS: SF-1 inhibitors of the alkyloxyphenol class displayed a dose-dependent inhibitory effect on both SF-1-positive and -negative ACT cells, whereas SF-1 inverse agonists of the isoquinolinone class selectively inhibited cell proliferation elicited by SF-1 overexpression. These drugs also inhibited stimulated steroid hormone secretion and CYP21 and CYP17 mRNA expression.
CONCLUSION: SF-1 inhibitors may represent a useful tool in the chemotherapy of ACTs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318454      PMCID: PMC2690427          DOI: 10.1210/jc.2008-2163

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.

Authors:  Joshua Roth; Franck Madoux; Peter Hodder; William R Roush
Journal:  Bioorg Med Chem Lett       Date:  2008-03-14       Impact factor: 2.823

3.  25-Hydroxycholesterol is not a ligand for the orphan nuclear receptor steroidogenic factor-1 (SF-1).

Authors:  S H Mellon; S R Bair
Journal:  Endocrinology       Date:  1998-06       Impact factor: 4.736

4.  SF-1 overexpression in childhood adrenocortical tumours.

Authors:  Mara A D Pianovski; Luciane R Cavalli; Bonald C Figueiredo; Savana C L Santos; Mabrouka Doghman; Raul C Ribeiro; Antonio G Oliveira; Edson Michalkiewicz; Giovanna A Rodrigues; Gerard Zambetti; Bassem R Haddad; Enzo Lalli
Journal:  Eur J Cancer       Date:  2006-03-29       Impact factor: 9.162

5.  Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids.

Authors:  Y Sadovsky; P A Crawford; K G Woodson; J A Polish; M A Clements; L M Tourtellotte; K Simburger; J Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

6.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Aaron C Spalding; Joanne H Heaton; Rork Kuick; Alex C Kim; Dafydd G Thomas; Thomas J Giordano; Edgar Ben-Josef; Gary D Hammer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

7.  Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening.

Authors:  Franck Madoux; Xiaolin Li; Peter Chase; Gina Zastrow; Michael D Cameron; Juliana J Conkright; Patrick R Griffin; Scott Thacher; Peter Hodder
Journal:  Mol Pharmacol       Date:  2008-03-11       Impact factor: 4.436

8.  Nephroblastoma overexpressed/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell proapoptotic factor, is down-regulated in childhood adrenocortical tumors.

Authors:  Mabrouka Doghman; Malika Arhatte; Hélène Thibout; Giovanna Rodrigues; Juliana De Moura; Sébastien Grosso; Alina Nico West; Maryvonne Laurent; Jean-Christophe Mas; André Bongain; Gerard P Zambetti; Bonald C Figueiredo; Patrick Auberger; Cécile Martinerie; Enzo Lalli
Journal:  J Clin Endocrinol Metab       Date:  2007-06-12       Impact factor: 5.958

9.  Differential effects of high and low steroidogenic factor-1 expression on CYP11B2 expression and aldosterone production in adrenocortical cells.

Authors:  Ping Ye; Yashuhiro Nakamura; Enzo Lalli; William E Rainey
Journal:  Endocrinology       Date:  2008-10-30       Impact factor: 4.736

10.  Identification of the first synthetic steroidogenic factor 1 inverse agonists: pharmacological modulation of steroidogenic enzymes.

Authors:  Andria L Del Tredici; Carsten B Andersen; Erika A Currier; Steven R Ohrmund; Luke C Fairbain; Birgitte W Lund; Norman Nash; Roger Olsson; Fabrice Piu
Journal:  Mol Pharmacol       Date:  2007-11-30       Impact factor: 4.436

View more
  29 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

3.  Steroidogenic Factor 1 (NR5A1) resides in centrosomes and maintains genomic stability by controlling centrosome homeostasis.

Authors:  P-Y Lai; C-Y Wang; W-Y Chen; Y-H Kao; H-M Tsai; T Tachibana; W-C Chang; B-c Chung
Journal:  Cell Death Differ       Date:  2011-05-13       Impact factor: 15.828

4.  Nuclear receptor profiling of ovarian granulosa cell tumors.

Authors:  Maria Alexiadis; Natalie Eriksson; Stacey Jamieson; Melissa Davis; Ann E Drummond; Simon Chu; Colin D Clyne; George E Muscat; Peter J Fuller
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

5.  Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.

Authors:  Ozgür Mete; Yersu Kapran; Mine G Güllüoğlu; Işin Kiliçaslan; Yeşim Erbil; Yasemin Giles Senyürek; Ferhunde Dizdaroğlu
Journal:  Virchows Arch       Date:  2010-05       Impact factor: 4.064

6.  Animal models of adrenocortical tumorigenesis.

Authors:  Felix Beuschlein; Sara Galac; David B Wilson
Journal:  Mol Cell Endocrinol       Date:  2011-11-11       Impact factor: 4.102

7.  Endometrial Expression of Steroidogenic Factor 1 Promotes Cystic Glandular Morphogenesis.

Authors:  Yasmin M Vasquez; San-Pin Wu; Matthew L Anderson; Shannon M Hawkins; Chad J Creighton; Madhumita Ray; Sophia Y Tsai; Ming-Jer Tsai; John P Lydon; Francesco J DeMayo
Journal:  Mol Endocrinol       Date:  2016-03-28

8.  Therapy of adrenocortical cancer: present and future.

Authors:  Daniela F Maluf; Brás H de Oliveira; Enzo Lalli
Journal:  Am J Cancer Res       Date:  2010-12-07       Impact factor: 6.166

Review 9.  Steroidogenic factor-1 and human disease.

Authors:  Ranna El-Khairi; John C Achermann
Journal:  Semin Reprod Med       Date:  2012-10-08       Impact factor: 1.303

Review 10.  Phospholipid--driven gene regulation.

Authors:  Paul M Musille; Jeffrey A Kohn; Eric A Ortlund
Journal:  FEBS Lett       Date:  2013-01-16       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.